Cell line · CVCL_0389
Papers32
1 to 20 of 32
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Neuronal differentiation of neuroblastoma cell lines for neurological disease modeling. | iScience | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Engineering functionality-optimized fully human B7-H3 CAR T cells for enhanced solid tumor therapy. | Cell Rep Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Extrachromosomal DNA-Driven Oncogene Dosage Heterogeneity Promotes Rapid Adaptation to Therapy in MYCN-Amplified Cancers. | Cancer Discov | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Serially Quantifying TERT Rearrangement Breakpoints in ctDNA Enables Minimal Residual Disease Monitoring in Patients with Neuroblastoma. | Cancer Res Commun | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Sustained cancer-relevant alternative RNA splicing events driven by PRMT5 in high-risk neuroblastoma. | Mol Oncol | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Targeting NRAS via miR-1304-5p or farnesyltransferase inhibition confers sensitivity to ALK inhibitors in ALK-mutant neuroblastoma. | Nat Commun | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Rejuvenated iPSC-derived GD2-directed CART Cells Harbor Robust Cytotoxicity Against Small Cell Lung Cancer. | Cancer Res Commun | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Systems-level analyses of protein-protein interaction network dysfunctions via epichaperomics identify cancer-specific mechanisms of stress adaptation. | Nat Commun | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Identification and targeting of protein tyrosine kinase 7 (PTK7) as an immunotherapy candidate for neuroblastoma. | Cell Rep Med | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Sex-specific declines in cholinergic-targeting tRNA fragments in the nucleus accumbens in Alzheimer's disease. | Alzheimers Dement | 2023 | Its Methods give the RRID and name the line | PubMed | |
| PubMed 36798311 | bioRxiv | 2023 | Its Methods give the RRID and name the line | PubMed | |
| ERBB and P-glycoprotein inhibitors break resistance in relapsed neuroblastoma models through P-glycoprotein. | Mol Oncol | 2023 | Its Methods give the RRID and name the line | PubMed | |
| MYCN-driven fatty acid uptake is a metabolic vulnerability in neuroblastoma. | Nat Commun | 2022 | Its Methods give the RRID and name the line | PubMed | |
| Translational Strategies for Repotrectinib in Neuroblastoma. | Mol Cancer Ther | 2021 | Its Methods give the RRID and name the line | PubMed | |
| Antibody-Drug Conjugate Efficacy in Neuroblastoma: Role of Payload, Resistance Mechanisms, Target Density, and Antibody Internalization. | Mol Cancer Ther | 2021 | Its Methods give the RRID and name the line | PubMed | |
| YKL-40 protein expression in human tumor samples and human tumor cell line xenografts: implications for its use in tumor models. | Cell Oncol (Dordr) | 2021 | Its Methods give the RRID and name the line | PubMed | |
| The identification of dual protective agents against cisplatin-induced oto- and nephrotoxicity using the zebrafish model. | Elife | 2020 | Its Methods give the RRID and name the line | PubMed | |
| Integrative Transcriptomics Reveals Sexually Dimorphic Control of the Cholinergic/Neurokine Interface in Schizophrenia and Bipolar Disorder. | Cell Rep | 2019 | Its Methods give the RRID and name the line | PubMed | |
| Transcriptomic profiling of 39 commonly-used neuroblastoma cell lines. | Sci Data | 2017 | Cellosaurus cites it | PubMed | |
| Alternative lengthening of telomeres in neuroblastoma cell lines is associated with a lack of MYCN genomic amplification and with p53 pathway aberrations. | J Neurooncol | 2014 | Cellosaurus cites it | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_0389/papers